G V Sanchez1, A M G Baird1, J A Karlowsky2, R N Master3, J M Bordon4. 1. School of Public Health and Health Services, The George Washington University, Washington, DC, USA School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA. 2. Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg R3E 0J9, Canada. 3. Quest Diagnostics Nichols Institute, Chantilly, VA, USA. 4. Section of Infectious Diseases, Providence Hospital, Washington, DC, USA jbordon@provhosp.org.
Abstract
OBJECTIVES: To examine the prevalence of multidrug-resistant (MDR) urinary Escherichia coli among US outpatients and to assess the antimicrobial activity of oral antibiotics commonly used to treat urinary tract infections (UTIs) against MDR isolates. METHODS: Antimicrobial susceptibility testing data from outpatient urine cultures in The Surveillance Network (TSN) Database USA were analysed. Six antimicrobial agents from six separate drug classes were included: ampicillin, cefalotin, ciprofloxacin, nitrofurantoin, trimethoprim/sulfamethoxazole and amoxicillin/clavulanate. Isolates were categorized as resistant to one, two, three, four, five and six agents and compared for the years 2001 and 2010. Phenotypes of MDR isolates were assessed to determine antimicrobial activity of recommended therapy for UTIs. RESULTS: Prevalence of MDR E. coli increased from 9.1% in 2001 (n = 29,198) to 17.0% in 2010 (n = 32,742) (P < 0.0001). In isolates that demonstrated resistance to three, four or five antimicrobial agents in 2010, resistance to nitrofurantoin was observed in only 2.1%, 7.5% and 24.1% of isolates, respectively. Conversely, widespread resistance was observed for trimethoprim/sulfamethoxazole (62.6%, 88.6% and 97.9% for isolates resistant to three, four and five agents, respectively) and ciprofloxacin (48.9%, 84.3% and 98.2% for isolates resistant to three, four and five agents, respectively). CONCLUSIONS: Because of its consistent antimicrobial activity against MDR E. coli, nitrofurantoin remains a reliable first-line agent for the empirical treatment of acute uncomplicated cystitis.
OBJECTIVES: To examine the prevalence of multidrug-resistant (MDR) urinary Escherichia coli among US outpatients and to assess the antimicrobial activity of oral antibiotics commonly used to treat urinary tract infections (UTIs) against MDR isolates. METHODS: Antimicrobial susceptibility testing data from outpatient urine cultures in The Surveillance Network (TSN) Database USA were analysed. Six antimicrobial agents from six separate drug classes were included: ampicillin, cefalotin, ciprofloxacin, nitrofurantoin, trimethoprim/sulfamethoxazole and amoxicillin/clavulanate. Isolates were categorized as resistant to one, two, three, four, five and six agents and compared for the years 2001 and 2010. Phenotypes of MDR isolates were assessed to determine antimicrobial activity of recommended therapy for UTIs. RESULTS: Prevalence of MDR E. coli increased from 9.1% in 2001 (n = 29,198) to 17.0% in 2010 (n = 32,742) (P < 0.0001). In isolates that demonstrated resistance to three, four or five antimicrobial agents in 2010, resistance to nitrofurantoin was observed in only 2.1%, 7.5% and 24.1% of isolates, respectively. Conversely, widespread resistance was observed for trimethoprim/sulfamethoxazole (62.6%, 88.6% and 97.9% for isolates resistant to three, four and five agents, respectively) and ciprofloxacin (48.9%, 84.3% and 98.2% for isolates resistant to three, four and five agents, respectively). CONCLUSIONS: Because of its consistent antimicrobial activity against MDR E. coli, nitrofurantoin remains a reliable first-line agent for the empirical treatment of acute uncomplicated cystitis.
Authors: Elizabeth B Hirsch; Paola C Zucchi; Alice Chen; Brian R Raux; James E Kirby; Christopher McCoy; George M Eliopoulos Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: Caroline G Elmer-Lyon; Judy A Streit; Elizabeth B Takacs; Patrick P Ten Eyck; Catherine S Bradley Journal: Int Urogynecol J Date: 2019-06-20 Impact factor: 2.894
Authors: B A Cunha; C B Cunha; B Lam; J Giuga; J Chin; V F Zafonte; S Gerson Journal: Eur J Clin Microbiol Infect Dis Date: 2017-02-02 Impact factor: 3.267
Authors: Miwako Kobayashi; Daniel J Shapiro; Adam L Hersh; Guillermo V Sanchez; Lauri A Hicks Journal: Open Forum Infect Dis Date: 2016-08-02 Impact factor: 3.835
Authors: Joan A Casey; Kara E Rudolph; Sarah C Robinson; Katia Bruxvoort; Eva Raphael; Vennis Hong; Alice Pressman; Rachel Morello-Frosch; Rong X Wei; Sara Y Tartof Journal: Open Forum Infect Dis Date: 2021-05-26 Impact factor: 3.835